JANSEN'S METAPHYSEAL CHONDRODYSPLASIA

Clinical trials for JANSEN'S METAPHYSEAL CHONDRODYSPLASIA explained in plain language.

Never miss a new study

Get alerted when new JANSEN'S METAPHYSEAL CHONDRODYSPLASIA trials appear

Sign up with your email to follow new studies for JANSEN'S METAPHYSEAL CHONDRODYSPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

First human trial launches for Ultra-Rare bone disorder

Disease control Recruiting now

This study tests a new drug, PTH-IA, for Jansen's metaphyseal chondrodysplasia (JMC), a very rare genetic bone disease affecting about 30 people worldwide. JMC causes severe short stature, frequent fractures, bone pain, and kidney problems. The drug aims to block overactive signa…

Matched conditions: JANSEN'S METAPHYSEAL CHONDRODYSPLASIA

Phase: PHASE1, PHASE2 • Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Disease control

Last updated May 22, 2026 14:05 UTC

JANSEN'S METAPHYSEAL CHONDRODYSPLASIA

Get alerted when new JANSEN'S METAPHYSEAL CHONDRODYSPLASIA trials appear

First human trial launches for Ultra-Rare bone disorder